Abstract
Carcinomas with neuroendocrine differentiation include tumor components with characteristics of neuroendocrine tumors of carcinomas of the lung, gastrointestinal tract, prostate, and breast. No clear definition or treatment has been established. A 66-year-old female was admitted to our hospital for a sore throat and otalgia. Magnetic resonance imaging showed a locally invasive tumor with a diameter of 45 mm in the clival region. Histopathological examination revealed that the tumor consisted of densely packed undifferentiated tumor cells with high mitotic activity. Two cellular components were present: one proliferating in solid nests that were immunopositive for cytokeratin, and the other that was diffusely proliferating and immunopositive for neuroendocrine markers. The tumor was thus diagnosed as undifferentiated carcinoma with neuroendocrine differentiation. The patient was treated with four cycles of cisplatin and etoposide and a total of 70 Gy radiotherapy. A complete response was achieved and maintained without therapy for 16 months. Metastasis to the lymph nodes, liver, and bone then appeared, and a lymphadenectomy revealed undifferentiated carcinoma without neuroendocrine differentiation. The patient died because of the tumor 36 months after the initial diagnosis. Because undifferentiated carcinomas with neuroendocrine differentiation in the skull are exceedingly rare, we report this case in which the tumor was controlled with chemoradiotherapy.
This is a preview of subscription content, log in via an institution to check access.
References
Strosberg JR, Coppola D, Klimstra DS et al (2010) The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas. Pancreas 39(6):799–800
Iwasa S, Morizane C, Okusaka T et al (2010) Cisplatin and Etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas. Jpn J Clin Oncol 40(4):313–318
Grabowski P, Schindler I, Anagnostopoulos I et al (2001) Neuroendocrine differentiation is a relevant prognostic factor in stage III–IV colorectal cancer. Eur J Gastroenterol Hepatol 13:405–411
Berruti A, Bollito E, Cracco M et al (2010) The prognostic role of immunohistochemical chromogranin a expression in prostate cancer patients is significantly modified by androgen-deprivation therapy. Prostate 70(7):718–726
Bosman FT, Carneiro F, Hruban RH et al (2010) WHO classification of tumours of the digestive system, 4th edn. IARC press, Lyons
National Comprehensive Cancer Network (NCCN) guidelines version 2.2014 small cell lung cancer
Jotte R, Conkling P, Reynolds C et al (2011) Randomised phaseIII trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy. J Clin Oncol 29(3):287–293
Helpap B, Köllermann J (2001) Immunohistochemical analysis of the proliferative activity of neuroendocrine tumors from various organs. Are there indications for a neuroendocrine tumor-carcinoma sequence? Virchow Arch 438:86–91
Grabowski P, Schönfelder J, Ahnert-Hilger G et al (2002) Expression of neuroendocrine markers: a signature of human undifferentiated carcinoma of the colon and rectum. Virchow Arch 441:256–263
Vortmeyer AO, Lubensky IA, Merino MJ et al (1997) Concordance of genetic alterations in poorly differentiated colorectal neuroendocrine carcinomas and associated adenocarcinomas. J Natl Cancer Inst 89:1448–1453
Conflict of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Takayoshi, K., Tamura, S., Uchino, K. et al. Successful multimodal therapy for undifferentiated carcinoma with neuroendocrine differentiation in the clival region. Int Canc Conf J 4, 105–110 (2015). https://doi.org/10.1007/s13691-014-0179-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13691-014-0179-1